| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 1, 2023 | COLL Collegium Pharmaceutical, Inc | Dreyer Scott54 | EVP &Chief Commercial Officer | Sell | 13,324 | $26.70 | $355,750.80 | -9.0% | -18.6% | +37.0% | |
| Mar 1, 2023 | AKBA Akebia Therapeutics, Inc. | Dahan Michel59 | SVP, Chief Operating Officer | Sell | 20,412 | $0.88 | $17,911.53 | -2.4% | +4.8% | +72.7% | |
| Mar 1, 2023 | HIMS Hims & Hers Health, Inc. | Carroll Patrick Harrison52 | Director | Sell | 20,857 | $11.70 | $244,026.90 | -16.9% | -23.0% | +13.1% | |
| Mar 1, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $245.24 | $3,923,810.23 | -30.2% | -16.2% | -7.9% | |
| Mar 1, 2023 | VRNO Verano Holdings Corp. | Smullen Richard Michael | Director | Sell | 48,300 | $2.92 | $141,174.70 | -0.6% | - | - | |
| Feb 28, 2023 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 63,383 | $9.89 | $626,642.37 | -91.4% | -27.2% | +32.1% | |
| Feb 28, 2023 | LQDA Liquidia Corp | Moomaw Scott | Chief Commercial Officer | Sell | 2,171 | $7.56 | $16,405.16 | -2.1% | +4.9% | +90.0% | |
| Feb 28, 2023 | TEVA Teva Pharmaceutical Industries Ltd | Drape Eric51 | Executive VP Global Operations | Sell | 33,685 | $9.89 | $333,030.12 | -14.5% | -27.2% | +32.1% | |
| Feb 28, 2023 | TEVA Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP, North America Commercial | Sell | 59,655 | $9.89 | $589,785.12 | -15.3% | -27.2% | +32.1% | |
| Feb 28, 2023 | LQDA Liquidia Corp | Lippe Robert A54 | Chief Operations Officer | Sell | 2,033 | $7.56 | $15,362.36 | -1.1% | +4.9% | +90.0% | |
| Feb 28, 2023 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 44,252 | $9.89 | $437,501.82 | -28.1% | -27.2% | +32.1% | |
| Feb 28, 2023 | VTRS Viatris Inc | Ni Xiangyang (sean)50 | President, Greater China | Sell | 5,250 | $11.22 | $58,893.45 | -12.4% | -19.5% | +7.8% | |
| Feb 28, 2023 | IRWD Ironwood Pharmaceuticals Inc | Rickard Jason65 | SVP, Chief Operating Officer | Sell | 34,175 | $11.36 | $388,193.85 | -2.4% | -4.6% | +34.2% | |
| Feb 28, 2023 | BHC Bausch Health Companies Inc. | Carson Seana60 | EVP, General Counsel | Sell | 292 | $9.32 | $2,721.44 | - | -12.0% | -1.2% | |
| Feb 28, 2023 | IRWD Ironwood Pharmaceuticals Inc | Silver Ronald68 | Principal Accounting Officer | Sell | 5,978 | $11.36 | $67,904.08 | -2.9% | -4.6% | +34.2% | |
| Feb 28, 2023 | IRWD Ironwood Pharmaceuticals Inc | McCourt Thomas A66 | Chief Executive Officer | Sell | 61,231 | $11.36 | $695,523.01 | -2.1% | -4.6% | +34.2% | |
| Feb 28, 2023 | IRWD Ironwood Pharmaceuticals Inc | Shetzline Michael67 | CMO,SVP,Head-res&Drug | Sell | 19,322 | $11.36 | $219,478.62 | -1.8% | -4.6% | +34.2% | |
| Feb 28, 2023 | IRWD Ironwood Pharmaceuticals Inc | Davis Andrew73 | SVP, Chief Business Officer | Sell | 3,573 | $11.36 | $40,585.73 | -1.2% | -4.6% | +34.2% | |
| Feb 28, 2023 | IRWD Ironwood Pharmaceuticals Inc | John Minardo69 | Chief Legal Officer | Sell | 6,697 | $11.36 | $76,071.27 | -2.4% | -4.6% | +34.2% | |
| Feb 27, 2023 | AKBA Akebia Therapeutics, Inc. | Butler John P.61 | CEO And President | Sell | 38,632 | $0.81 | $31,415.54 | -2.3% | +17.5% | +101.1% | |
| Feb 27, 2023 | AKBA Akebia Therapeutics, Inc. | Hadas Nicole R.60 | SVP, Chief Legal Officer | Sell | 6,677 | $0.81 | $5,429.74 | -2.2% | +17.5% | +101.1% | |
| Feb 27, 2023 | AKBA Akebia Therapeutics, Inc. | Burke Steven Keith61 | SVP, Chief Medical Officer | Sell | 7,539 | $0.81 | $6,130.71 | -1.2% | +17.5% | +101.1% | |
| Feb 27, 2023 | AKBA Akebia Therapeutics, Inc. | Dahan Michel59 | SVP, Chief Operating Officer | Sell | 10,090 | $0.81 | $8,205.19 | -3.4% | +17.5% | +101.1% | |
| Feb 27, 2023 | DVAX Dynavax Technologies Corp | Burgess Justin60 | Chief Accounting Officer | Sell | 22,371 | $10.38 | $232,146.22 | -38.4% | +8.4% | +25.4% | |
| Feb 27, 2023 | AKBA Akebia Therapeutics, Inc. | Spellman David A52 | SVP, CFO And Treasurer | Sell | 7,539 | $0.81 | $6,130.71 | -1.4% | +17.5% | +101.1% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.